Safety and Efficacy of Multiple EPO Injections in Children With Cerebral Palsy

Bundang CHA Hospital

Status: Completed

Conditions: Cerebral Palsy

Treatments: Drug: recombinant human erythropoietin

Study type: Observational

Funder types: Other

Identifiers

NCT03303573

Multiple EPO

Details and patient eligibility

About

This study is a retrospective review on the safety and efficacy of repetitive erythropoietin injection in children with cerebral palsy

Full description

Cerebral palsy is mostly caused by hypoxic-ischemic encephalopathy from preterm birth, involving inflammatory and apoptotic cellular response. Erythropoietin (EPO) has shown neuroprotective effects via activation of anti-inflammatory, angiogenic, and anti-apoptotic pathways. The safety and feasibility of EPO in children were proven in previous clinical trials. In addition, the efficacy of EPO is actively being investigated and some reports have shown potential benefits in cerebral palsy. To confirm the safety and efficacy of multiple injections with expected effect, retrospective review on medical records was performed.

Enrollment: 164 patients

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

• confirmed clinical diagnosis of cerebral palsy based on neuromotor findings,
• less than 18 years of age,
• received recombinant human erythropoietin (rhEPO) more than once.

Exclusion criteria

• not responding to phone interview or
• no functional assessments available.

Trial design

164 participants in 1 patient group

recombinant human erythropoietin group

Description:

cerebral palsy patients who had received erythropoietin from January 2013 to November 2016

Treatment:

Drug: recombinant human erythropoietin